ProPhase LabsPRPH Debt-to-EBITDA is -1.02 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 892856.25% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ProPhase Labs's Debt-to-EBITDA or its related term are showing as below:
PRPH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.43 Med: -0.76 Max: 1.49
Current: -1.11
During the past 13 years, the highest Debt-to-EBITDA Ratio of ProPhase Labs was 1.49. The lowest was -9.43. And the median was -0.76.
PRPH's Debt-to-EBITDA is ranked worse than 100% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.29
vs PRPH: -1.11
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ProPhase Labs Debt-to-EBITDA Related Terms
ProPhase Labs Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, IVRO, FUNI: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
ProPhase Labs (PRPH) has a Debt-to-EBITDA of -1.02 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ProPhase Labs. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 112 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Debt-to-EBITDA too high?
ProPhase Labs' current Debt-to-EBITDA is -1.02. Based on the distribution chart, ProPhase Labs ranks #999999 out of 112 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Debt-to-EBITDA compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 112 companies for Debt-to-EBITDA. This places ProPhase Labs in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.29, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ProPhase Labs. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Debt-to-EBITDA is -1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.92, compared to a current price of $0.08 — trading 91.7% below its estimated fair value. The current Debt-to-EBITDA is -1.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Debt-to-EBITDA is -1.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 